L&K Biopharm (엘앤케이바이오)
KOSDAQ · KRX: 156100
L&K Biopharm is a South Korean biopharmaceutical company that develops and manufactures pharmaceutical products, with a focus on oncology and other therapeutic areas. The company is listed on the KOSDAQ market, South Korea's secondary stock exchange for small and mid-sized enterprises.
Filing timeline
highspotted 17:40 KST
L&K Biopharm (KRX: 156100)- Kang Guk-jin (강국진), reported as largest shareholder, now holds 2,725,668 shares representing 12.19% of outstanding shares as of 3 August 2026
- Controlled shares total 778,359 (3.48% stake); irrevocable deposit shares total 36,630 (0.16% stake)
- Report filed under standard large shareholder disclosure rules; stated reason: additional share purchase by largest shareholder
View original DART filing ↗mediumspotted 17:40 KST
L&K Biopharm (KRX: 156100)- Kang Guk-jin, representative director (대표이사) and registered executive officer (등기임원), reported ownership of 2,553,789 shares as of filing date 3 August 2026.
- Stake represents 11.43% of outstanding shares, qualifying him as a major shareholder (10% 이상주주).
- Pledged shares total 36,630 units (0.08% of total shares), indicating collateralised debt against a portion of his holding.
View original DART filing ↗AI-generated summaries of public DART filings. May contain errors — always verify against the original (linked). Not investment advice.